Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02203591 · ClinicalTrials.gov registry record · Phase 3
In Vivo Efficacy Study of Patient Preoperative Preps
A Phase 3 study, sponsored by 3M.
- Completed
- Registry status
- Phase 3
- Development phase
- 738
- Enrollment target
NCT02203591: Completed Phase 3 study, sponsored by 3M.
NCT02203591 is a Phase 3 study that has completed, run by 3M. The registered enrollment target is 738 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02203591, a Phase 3 study, has completed, sponsored by 3M.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 738 participants
- Enrollment target
Study Summary
The objective of this study is to demonstrate the antimicrobial efficacy of the 3M CHG/IPA Prep on skin flora of the abdominal and inguinal regions of human subjects.
Primary Outcome
On the abdominal region a responder is a subject with a 2 log10/cm\^2 bacterial reduction at 10 minutes and for whom the skin flora does not return to baseline at the 6-hour sample collection time. On the inguinal region a responder is a subject with a 3 log10/cm\^2 bacterial reduction at 10 minutes and for whom the skin flora does not return to baseline at the 6-hour sample collection time.
Interventions
- DRUG Normal Saline
- DRUG ChloraPrep
- DRUG 3M CHG/IPA Prep C
- DRUG 3M CHG/IPA Prep CH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 738 participants |
| Start Date | 2014-07 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
What the finished NCT02203591 record still lists
NCT02203591 is an interventional study that assigns participants to a tested intervention. The registered 738 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Normal Saline is the first listed.
NCT02203591 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02203591 about?
NCT02203591 is a clinical study titled "In Vivo Efficacy Study of Patient Preoperative Preps". The objective of this study is to demonstrate the antimicrobial efficacy of the 3M CHG/IPA Prep on skin flora of the abdominal and inguinal regions of human subjects.
What is the current status of trial NCT02203591?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 738 participants. The study started on 2014-07. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02203591?
The interventions under investigation include: Normal Saline (DRUG), ChloraPrep (DRUG), 3M CHG/IPA Prep C (DRUG), 3M CHG/IPA Prep CH (DRUG).
Who is sponsoring clinical trial NCT02203591?
This trial is sponsored by 3M, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02203591's enrollment target sits among peer trials
738 479th of 2000 higher than 1,522 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03723928 · 739 participants · NA
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
- NCT03963622 · 740 participants · NA
Careful Ventilation in Acute Respiratory Distress Syndrome (COVID-19 and Non-COVID-19)
- NCT04074135 · 740 participants · Phase 2
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
- NCT05215340 · 740 participants · Phase 3
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia